Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL189878 | 1.00 | TDP1 (0.44) | TDP1NR1I2PTGS1ADRA1ALMNA | |
| SCHEMBL28688103 | 1.00 | TDP1 (0.44) | TDP1NR1I2PTGS1ADRA1ALMNA | |
| Iodide SCHEMBL27294834 | 0.98 | TDP1 (0.43) | TDP1NR1I2PTGS1ADRA1ALMNA | |
| Methane SCHEMBL20292606 | 0.98 | TDP1 (0.43) | TDP1NR1I2PTGS1ADRA1ALMNA | |
| SCHEMBL14935915 | 0.83 | CYP2D6 (0.48) | LMNASRCKMT2AMEN1CYP2C9 | |
| SCHEMBL2939473 | 0.83 | CYP2D6 (0.48) | LMNASRCKMT2AMEN1CYP2C9 | |
| Methane SCHEMBL5182249 | 0.82 | CYP2D6 (0.46) | LMNASRCKMT2AMEN1CYP2C9 | |
| Methane SCHEMBL5182658 | 0.82 | CYP2D6 (0.46) | LMNASRCKMT2AMEN1CYP2C9 | |
| SCHEMBL3666840 | 0.79 | SRC (0.47) | TDP1PTGS1ADRA1ALMNASRC | |
| SCHEMBL6046193 | 0.79 | TDP1 (0.47) | TDP1NR1I2PTGS1ADRA1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590345-A2 | HIGH-PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Nuclidium AG (CH) | 2025-07-30 | — | — | EP | claimed |
| WO-2024064969-A2 | HIGH-PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2024-03-28 | — | — | WO | claimed |
| US-20260137818-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2026-05-21 | — | — | US | disclosed |
| US-12622984-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | NUCLIDIUM AG (CH) | 2026-05-12 | — | — | US | disclosed |
| US-12527885-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | NUCLIDIUM AG (CH) | 2026-01-20 | — | — | US | disclosed |
| EP-4590345-A2 | HIGH-PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Nuclidium AG (CH) | 2025-07-30 | — | — | EP | disclosed |
| US-20240189460-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2024-06-13 | — | — | US | disclosed |
| US-20240173441-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2024-05-30 | — | — | US | disclosed |
| US-20240173440-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2024-05-30 | — | — | US | disclosed |
| WO-2024064969-A2 | HIGH-PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2024-03-28 | — | — | WO | disclosed |
| US-20240067599-A1 | IODOTYROSINE DERIVATIVES AND PROCESS FOR PREPARING IODOTYROSINE DERIVATIVES | ABX ADVANCED BIOCHEMICAL COMPOUNDS - BIOMEDIZINISCHE FORSCHUNGSREAGENZIEN GMBH (DE) | 2024-02-29 | — | — | US | disclosed |
| EP-1161449-B1 | MODULATORS OF BETA-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | PRAECIS PHARM INC (US) | 2007-07-04 | — | — | EP | disclosed |
| CN-1279053-C | Modulators for beta-amyloid peptide aggregation comprising D-amino acids | PRAECIS PHARM INC (US) | 2006-10-11 | — | — | CN | disclosed |
| US-20050137128-A1 | Modulators of ß-amyloid peptide aggregation | PRAECIS PHARMACEUTICALS, INC. (US) | 2005-06-23 | — | — | US | disclosed |
| US-6831066-B2 | Amyloid precursor proteins with improved bioavailability; for treament of Alzheimer's disease | PRAECIS PHARMACEUTICALS INCORPORATED | 2004-12-14 | — | — | US | disclosed |
| US-6610658-B1 | Oligopeptides used as time release agents, for transporting drugs across the blood-brain barrier, medical diagnosis and therapy for amyloidosis such as Alzheimer's disease | PRAECIS PHARMACEUTICALS INC. | 2003-08-26 | — | — | US | disclosed |
| CN-1362967-A | D-amino acid-containing regulator of beta-amyloid peptide aggregation | PRAECIS PHARM INC (US) | 2002-08-07 | — | — | CN | disclosed |
| WO-2000052048-A9 | MODULATORS OF BETA-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | PRAECIS PHARM INC (US) | 2002-04-11 | — | — | WO | disclosed |
| EP-1161449-A1 | MODULATORS OF BETA-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | Praecis Pharmaceuticals Incorporated (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000052048-A1 | MODULATORS OF BETA-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527885-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | SSTR1, PSMA1, KLK3 | TDP1 2926/4885NR1I2 1772/4885PTGS1 2635/4885 |
| US-20240173441-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | SSTR1, SSTR3, SSTR2 | TDP1 3119/4885NR1I2 2430/4885PTGS1 4468/4885 |
| US-20260137818-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | FAP, SSTR1, PSMA1 | TDP1 1379/4885NR1I2 3584/4885PTGS1 1650/4885 |
| US-20240173440-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | SSTR1, SSTR3, SSTR2 | TDP1 3119/4885NR1I2 2430/4885PTGS1 4468/4885 |
| US-20240067599-A1 | IODOTYROSINE DERIVATIVES AND PROCESS FOR PREPARING IODOTYROSINE DERIVATIVES | ALK, ALKBH3, INSR | TDP1 3729/4885NR1I2 2633/4885PTGS1 3707/4885 |
| US-20050137128-A1 | Modulators of ß-amyloid peptide aggregation | APP, IAPP, BACE1 | TDP1 2532/4885NR1I2 1826/4885PTGS1 4578/4885 |
| US-20240189460-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | SSTR1, SSTR3, SSTR2 | TDP1 3119/4885NR1I2 2430/4885PTGS1 4468/4885 |
| US-12622984-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | SSTR2, SSTR1, SSTR3 | TDP1 3699/4885NR1I2 722/4885PTGS1 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.